Ochromycinone (STA-21) is primarily studied for its potential in cancer research due to its ability to inhibit STAT3 signaling, a pathway often implicated in tumor growth and survival. It has shown promise in preclinical studies for suppressing the proliferation of various cancer cells, including those in breast, prostate, and pancreatic cancers. Additionally, its role in inducing apoptosis in cancer cells makes it a candidate for further investigation in developing targeted cancer therapies. Beyond oncology, research explores its anti-inflammatory properties, suggesting potential applications in treating inflammatory diseases. However, its use remains largely experimental, with ongoing studies to evaluate its efficacy and safety.